Crossmark

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs

Crossref DOI link: https://doi.org/10.1186/s13722-021-00272-4

Published Online: 2021-10-24

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Scott, Travis M. http://orcid.org/0000-0002-2089-4967
Arnsten, Julia

Olsen, James Patrick

Arias, Franchesca

Cunningham, Chinazo O.

Rivera Mindt, Monica
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01733693 at ClinicalTrials.gov

Documents that mention this clinical trial

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
https://doi.org/10.1186/s13722-021-00272-4
Funding

Funding for this research was provided by:

National Institute on Drug Abuse (R01DA032552, R01DA032552)
License Information

Text and Data Mining valid from 2021-10-24

Version of Record valid from 2021-10-24
More Information

Article History

Received: 19 May 2021

Accepted: 12 October 2021

First Online: 24 October 2021

Declarations

:

: The trial was approved by the Institutional Review Boards of both Albert Einstein College of Medicine/Montefiore Medical Center and Fordham University. Informed consent was collected for all participants in this study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below